Business context and reporting period
The supplied filing is Organovo Holdings, Inc.’s Form 10-Q for the quarter ended September 30, 2014 (its fiscal 2015 second quarter), not a filing identified as Vivosim Labs, Inc. Organovo was developing and commercializing 3D human tissues for research, drug development, and potential therapeutic use. It reported no significant revenue from planned principal operations.
Key financial metrics
Amounts are in U.S. dollars; financial statement figures below are in millions except per-share data.
| Metric | Three months ended Sept. 30, 2014 | Six months ended Sept. 30, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $0.050 | $0.149 | $0.023 and $0.129 |
| Operating expenses | $9.006 | $15.515 | $5.625 and $9.465 |
| Operating loss | $(8.956) | $(15.366) | $(5.602) and $(9.336) |
| Net loss | $(8.858) | $(15.291) | $(10.386) and $(14.157) |
| Basic and diluted loss per share | $(0.11) | $(0.19) | $(0.14) and $(0.21) |
| Net cash used in operations | Not presented quarterly | $(9.677) | $(6.256) for six months |
Revenue was primarily from collaboration research agreements, with grant revenue also contributing. The filing does not provide a meaningful gross margin measure. At September 30, cash and cash equivalents were $54.389 million; current assets were $55.105 million and current liabilities $3.112 million, giving working capital of approximately $52.0 million. Total liabilities were $3.114 million, including $0.010 million of current and $0.001 million of long-term capital lease obligations. The company had an accumulated deficit of $107.504 million.
Material changes versus prior comparable periods
- Quarterly revenue increased $27,000 year over year; six-month revenue increased $20,000.
- Operating expenses rose 61% for the quarter and 64% for the six months. R&D expense increased to $3.229 million for the quarter and $6.043 million for the six months; SG&A increased to $5.777 million and $9.472 million, respectively.
- Management attributed higher costs to hiring, expanded research and development, commercialization preparation, facility expansion, public-company costs, and increased stock-based compensation. R&D headcount rose from 24 to 44; administrative headcount rose from 12 to 16.
- Six-month operating cash use increased to $9.677 million from $6.256 million. Financing provided $16.475 million, chiefly reflecting $16.1 million net proceeds from at-the-market stock sales; cash increased by $6.222 million over the period.
- Net loss improved year over year despite higher operating costs, largely because the prior-year periods included approximately $4.8 million of warrant-liability revaluation expense. The current-period fair-value change produced income of $64,000 for six months, a noncash item.
Outlook, risks, contingencies, and unusual items
- Management said available cash and expected receipts were sufficient to fund planned operations for at least 12 months, but stated that additional capital would be needed for further development and commercialization. Future financing may be unavailable or dilutive; grants and collaboration or product revenues are uncertain.
- In October 2014, the company amended its research agreement with United Therapeutics to expand the research scope; the extended agreement runs through December 2015.
- The company reported a pending dispute with Spencer Trask Ventures involving claims for compensation and alleged confidentiality breaches. It disputed the claims; no loss accrual was recorded, and the company said it could not estimate a possible loss.
- The facility lease expansion commenced September 1, 2014. Future minimum operating lease payments were approximately $6.966 million in total.
- Newly highlighted risks included difficulty attracting or retaining key personnel and cybersecurity incidents. The filing also cited technology-development, commercialization, and financing risks.
- Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported. No specific earnings or revenue guidance was provided.
Most important facts for investors to verify
- Confirm the issuer identity: the provided filing is for Organovo Holdings, Inc., not Vivosim Labs, Inc.
- Assess whether the stated 12-month cash runway remains adequate in light of the operating cash burn and planned R&D and commercialization spending.
- Review revenue growth, collaboration and grant milestones, and whether these can meaningfully offset rising operating expenses.
- Track equity issuance and potential dilution, including shares reserved for options and warrants.
- Monitor the Spencer Trask dispute, lease commitments, and execution of the expanded United Therapeutics research agreement.